Millennium Pharmaceuticals, Inc

Jun 20, 08 NEW STORY 18:59 ET FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma      May 31, 08 17:37 ET Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma      10:51 ET VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma      May 16, 08 12:50 ET New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma      Apr 29, 08 07:00 ET Takeda and Millennium Announce Early Termination of Hart-Scott-Rodino Waiting Period      Apr 10, 08 02:15 ET Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales      02:06 ET Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion      Mar 17, 08 07:01 ET Millennium Expands IBD Franchise with Addition of New Development Candidate      Mar 13, 08 07:01 ET Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients      Mar 12, 08 08:01 ET Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation      Mar 10, 08 08:01 ET Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation      Feb 28, 08 17:33 ET 2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation      Feb 20, 08 08:45 ET Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma      Feb 07, 08 07:01 ET Millennium Over-Delivers on 2007 Goals and Financial Guidance      Feb 04, 08 16:01 ET BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation      Jan 31, 08 16:01 ET 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation      07:01 ET Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology      Jan 24, 08 16:01 ET Wachovia 2008 Healthcare Conference to Webcast Millennium Presentation   Jan 04, 08 07:01 ET Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results      Jan 02, 08 08:01 ET 26th Annual JPMorgan Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Dec 28, 07 08:01 ET Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection      Dec 27, 07 16:01 ET Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference      Dec 21, 07 07:00 ET Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma      Dec 10, 07 15:02 ET VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial      Dec 09, 07 20:43 ET Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma      17:40 ET Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy      Dec 03, 07 17:27 ET Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event      Nov 26, 07 08:00 ET New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma      Nov 20, 07 16:01 ET BMO Capital Markets Healthcare Conference to Webcast Millennium Presentation      16:01 ET Piper Jaffray 19th Annual Healthcare Conference to Webcast Millennium Presentation      Nov 08, 07 09:04 ET Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders      Nov 06, 07 14:17 ET Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders      Nov 05, 07 16:01 ET 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation      Nov 01, 07 07:01 ET Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales      Oct 30, 07 10:26 ET CIBC World Markets 18th Annual Healthcare Conference to Webcast Millennium Presentation      Oct 25, 07 09:35 ET Millennium to Webcast Third-Quarter 2007 Financial and Operational Results      Oct 15, 07 09:00 ET FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma      Oct 04, 07 07:01 ET Life Sciences Leader Joins Millennium Board of Directors      Sep 20, 07 16:01 ET UBS Global Life Sciences Conference To Webcast Millennium Presentation      Sep 18, 07 07:01 ET Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints      Sep 13, 07 16:01 ET Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation      Sep 04, 07 08:01 ET Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation      Aug 29, 07 16:01 ET Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation   Aug 15, 07 08:01 ET Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma      Jul 26, 07 07:01 ET Millennium Highlights Strong Second-Quarter Results and Upcoming Growth Catalysts      Jul 19, 07 16:01 ET Millennium to Webcast Second-Quarter 2007 Financial and Operational Results      Jul 16, 07 08:01 ET Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients      Jul 02, 07 08:01 ET VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival      Jun 28, 07 12:00 ET VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications Associated with Multiple Myeloma      11:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma      10:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients      Jun 19, 07 08:01 ET VELCADE(R) (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop      Jun 05, 07 16:01 ET Goldman Sachs 28th Annual Global Healthcare Conference To Webcast Millennium Presentation      Jun 04, 07 15:01 ET New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma      Jun 03, 07 17:46 ET Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models      15:01 ET VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients      11:01 ET VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients      09:01 ET Millennium Advances Aurora A Kinase Program      Jun 01, 07 08:05 ET Bear Stearns 2007 Biotech Confab To Webcast Millennium Presentation      08:00 ET Millennium Appoints Three New Members to Executive Management Team      May 29, 07 08:01 ET VELCADE(R) (Bortezomib) for Injection to be Featured at Upcoming American Society of Clinical Oncology Meeting      May 24, 07 16:01 ET Bank of America 2007 Healthcare Conference to Webcast Millennium Presentation      May 17, 07 16:01 ET Citigroup 2007 Healthcare Conference to Webcast Millennium Presentation      08:01 ET Millennium Resumes Clinical Program for MLN0002      May 09, 07 16:01 ET Millennium to Webcast 2007 Annual Meeting of Stockholders      May 01, 07 16:00 ET Robert W. Baird 2007 Growth Stock Conference to Webcast Millennium Presentation      Apr 27, 07 16:01 ET Morgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Apr 26, 07 07:01 ET Millennium Reports Strong Financial and Operational Results for First Quarter 2007      Apr 19, 07 16:07 ET Millennium to Webcast First-Quarter 2007 Financial Results      Apr 17, 07 08:05 ET Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection      Apr 06, 07 16:01 ET CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Mar 12, 07 16:01 ET Lehman Brothers Tenth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Mar 07, 07 16:01 ET Cowen and Company 27th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Feb 08, 07 07:01 ET Millennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP Net Loss by 78%(1)      Feb 07, 07 16:11 ET BIO CEO & Investor 2007 Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Feb 01, 07 16:44 ET 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Jan 04, 07 16:01 ET Millennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss      Jan 02, 07 08:01 ET JPMorgan 25th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 29, 06 09:01 ET Millennium to Webcast Business Update in Advance of 25th Annual JPMorgan Healthcare Conference      Dec 14, 06 08:01 ET Dr. Bob Tepper, President of R&D, to Leave Millennium      Dec 12, 06 16:01 ET VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma      09:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Show Consistently High Complete and Near complete Response Rates in Front-Line Multiple Myeloma Trials      Dec 11, 06 16:15 ET VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas      12:00 ET Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma      10:30 ET Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection      Dec 10, 06 16:45 ET VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial      Dec 08, 06 16:41 ET Significant Data on VELCADE(R) (bortezomib) For Injection To Be Presented at Upcoming American Society of Hematology Meeting      Dec 04, 06 09:00 ET Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers      Nov 28, 06 10:15 ET Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis      Nov 22, 06 16:01 ET Piper Jaffray Health Care Conference to Webcast Millennium Presentation      Nov 15, 06 16:01 ET Millennium Closes Sale of $250.0 Million in Convertible Senior Notes      Nov 09, 06 20:02 ET Millennium Prices $225.0 Million in Convertible Senior Notes      06:54 ET Millennium Announces Proposed Offering of $200 Million in Convertible Senior Notes      Nov 02, 06 16:01 ET CIBC World Markets 17th Annual Healthcare Conference to Webcast Millennium Presentation      Oct 30, 06 16:01 ET MassOpps Investment Conference to Webcast Millennium Presentation      Oct 26, 06 07:01 ET Millennium Achieves Non-GAAP Profitability and Reduces GAAP Net Loss for Third Consecutive Quarter(1)      07:00 ET Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection      Oct 19, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Third-Quarter 2006 Financial Results      Oct 17, 06 03:01 ET Millennium Issues Statement Regarding AnorMED Inc.      Oct 06, 06 08:36 ET Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma      Sep 26, 06 09:46 ET Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date      Sep 18, 06 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Presentation      Sep 11, 06 16:06 ET Leerink Swann & Company / MEDACorp Cancer Roundtable Conference to Webcast Millennium Presentation      Sep 05, 06 16:02 ET Bear Stearns 19th Annual Healthcare Conference to Webcast Millennium Presentation      16:01 ET Thomas Weisel Partners Healthcare Conference 2006 to Webcast Millennium Presentation      Aug 30, 06 08:01 ET Millennium Announces Phase I Trial of MLN0415 for Inflammatory Disorders      Aug 09, 06 08:01 ET FDA Grants Priority Review to VELCADE(R) (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma      Jul 27, 06 07:01 ET Millennium Reports Strong Financial Results and Significant Accomplishment Toward 2006 Goals      Jul 26, 06 16:01 ET Baird 2006 Focus on Oncology Conference to Webcast Millennium Presentation      Jul 20, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Second-Quarter 2006 Financial Results      Jun 21, 06 11:55 ET VELCADE(R) (Bortezomib) for Injection Showed Unprecedented Results In Newly Diagnosed Multiple Myeloma Patients      Jun 15, 06 14:21 ET Millennium Responds to Market Report      Jun 09, 06 08:01 ET Millennium Files sNDA for VELCADE(R) (Bortezomib) for Injection in Treatment of Relapsed or Refractory Mantle Cell Lymphoma      Jun 06, 06 16:01 ET Goldman Sachs 27th Annual Healthcare Conference to Webcast Millennium Presentation      Jun 05, 06 14:05 ET Data at ASCO Demonstrate Potential of VELCADE(R) (Bortezomib) for Injection Across Solid and Hematological Cancers      Jun 04, 06 15:35 ET Addition of VELCADE(R) (Bortezomib) for Injection Improved survival in Front-Line Advanced Lung Cancer      10:50 ET VELCADE(R) (Bortezomib) for Injection May Offer New Standard of Care in Relapsed/Refractory Mantle Cell Lymphoma      10:05 ET VELCADE(R) (Bortezomib) for Injection Demonstrated High Single-Agent Response Rates in Newly Diagnosed Multiple Myeloma Patients      May 31, 06 08:01 ET Millennium Announces MLN1202 Fully Met Primary Endpoint in Phase II Clinical Study of Patients at High Risk for Atherosclerosis      May 25, 06 16:01 ET Bear Stearns Biotech Boston Confab to Webcast Millennium Presentation      May 04, 06 16:01 ET Baird 2006 Growth Stock Conference to Webcast Millennium Presentation      Apr 28, 06 16:01 ET Morgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Presentation      Apr 27, 06 16:01 ET Millennium Pharmaceuticals to Webcast 2006 Annual Meeting of Stockholders      07:01 ET Millennium Achieves First Quarter 2006 Non-GAAP Profitability and Reduces GAAP Net Loss      Apr 20, 06 17:05 ET Millennium Pharmaceuticals to Ring the NASDAQ Opening Bell in Conjunction with First Quarter 2006 Financial Results Conference Call      Apr 18, 06 08:01 ET Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma      Mar 09, 06 08:03 ET Millennium Achieves $10 Million Milestone Payment      Mar 06, 06 08:02 ET Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer      Mar 02, 06 16:01 ET Lehman Brothers Ninth Annual Global Healthcare Conference to Webcast Millennium Presentation   Feb 27, 06 16:01 ET SG Cowen & Co. 26th Annual Health Care Conference to Webcast Millennium Presentation      Feb 17, 06 16:01 ET Citigroup 2006 Healthcare Conference to Webcast Millennium Presentation      Feb 09, 06 08:02 ET Millennium Announces New Senior Vice President of Human Resources      Feb 06, 06 08:03 ET Millennium Announces Pharmaceutical Industry Leader Joins the Board Of Directors      Jan 31, 06 16:01 ET Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Millennium Presentation      Jan 26, 06 07:02 ET Millennium Achieves 2005 Financial Guidance      Jan 25, 06 08:32 ET Millennium Announces Appointments of Executive Vice President of Commercial Operations, Vice President of Finance and Several Key Promotions      Jan 20, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Full-Year 2005 Financial Results      Jan 05, 06 16:01 ET Millennium Details Strategic Drivers for Profitable Growth and 2006 Goals; Highlights 2005 Accomplishments      08:02 ET JPMorgan 24th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 30, 05 08:01 ET Millennium to Webcast Business Update in Advance of 24th Annual JPMorgan Healthcare Conference      Dec 13, 05 09:45 ET Consistently High Complete and Overall Response Rates in Newly-Diagnosed Multiple Myeloma Patients Shown With Velcade(R) (bortezomib) for Injection Based Therapies      Dec 12, 05 18:35 ET VELCADE(R) (bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients      17:39 ET VELCADE(R) (bortezomib) for Injection Continues to Show Impressive Results in a Variety of Lymphomas      Dec 11, 05 09:15 ET New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib) for Injection in Relapsed Multiple Myeloma      Dec 08, 05 16:01 ET Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) for Injection From the 47th Annual Meeting of the American Society of Hematology      Dec 06, 05 13:41 ET New Data on VELCADE(R) (bortezomib) for Injection to Be Presented at Upcoming American Society of Hematology Meeting      Nov 10, 05 16:01 ET 2005 Credit Suisse First Boston Health Care Conference to Webcast Millennium Presentation      Nov 03, 05 16:27 ET Millennium Initiates Trial of Novel Aurora Kinase Inhibitor MLN8054 in Advanced Solid Tumors      Nov 02, 05 12:00 ET Millennium Announces Clinical Updates at Analyst Day Meeting      Oct 31, 05 16:01 ET CIBC World Markets Sixteenth Annual Healthcare Conference to Webcast Millennium Presentation      Oct 28, 05 16:01 ET MassOpps Investment Conference to Webcast Millennium Presentation      Oct 27, 05 16:10 ET Millennium Announces Webcast of Analyst & Investor Day 2005 Presentations      Oct 26, 05 16:03 ET Millennium Reports Strong Third Quarter 2005 Financial Results      Oct 20, 05 08:01 ET Millennium Senior Vice President Abbie Celniker Receives Honors from Massachusetts Technology Leadership Council      Oct 19, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Third Quarter Financial Results      Oct 17, 05 08:03 ET Millennium Initiates Combination Phase I/II Trial of MLN518 in Acute Myelogenous Leukemia      Sep 13, 05 16:09 ET Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation      Sep 06, 05 16:01 ET Bear Stearns 18th Annual Healthcare Conference to Webcast Millennium Presentation      Sep 02, 05 16:01 ET NewsMakers in the Biotech Industry Conference to Webcast Millennium Presentation      Sep 01, 05 16:01 ET Thomas Weisel Partners Healthcare Tailwinds Conference 2005 to Webcast Millennium Presentation      Aug 18, 05 08:01 ET Millennium Initiates Phase II Clinical Trial to Evaluate MLN1202 in Cardiovascular Disease      Jul 28, 05 07:07 ET Millennium Reports Second Quarter 2005 Financial Results      Jul 21, 05 16:24 ET Millennium Pharmaceuticals to Webcast Conference Call on Second Quarter Financial Results      Jul 11, 05 07:01 ET Millennium Initiates Phase II Clinical Trial in Patients With Multiple Sclerosis      Jun 29, 05 07:50 ET Millennium Announces New CEO      Jun 28, 05 08:02 ET EARLY ACS Trial Designed to Reinforce Benefit of Early Use of INTEGRILIN(R) (eptifibatide) Injection in Contemporary nSTE ACS Setting      Jun 17, 05 08:01 ET Millennium Announces Appointment to Board of Directors      Jun 16, 05 08:01 ET New England Journal of Medicine Publishes Studies of VELCADE(R) (bortezomib) for Injection in Multiple Myeloma and MLN02 in Ulcerative Colitis      Jun 13, 05 08:04 ET VELCADE(R) (bortezomib) for Injection Showed Positive Activity Across a Variety of Lymphomas      Jun 10, 05 16:01 ET Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference to Webcast Millennium Presentation      Jun 08, 05 07:01 ET Two New Studies in the British Journal of Haematology Show Potential Role of VELCADE(R) (Bortezomib) for Injection in Treating Patients with Front-Line Multiple Myeloma      May 17, 05 08:03 ET New Front-Line Data at ASCO in Multiple Myeloma Support Important Role of VELCADE(R) (bortezomib) for Injection      May 14, 05 08:01 ET Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented      May 11, 05 16:01 ET Banc of America Securities Health Care Conference 2005 to Webcast Millennium Presentation      May 09, 05 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event      May 05, 05 16:56 ET Robert W. Baird & Co. 2005 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation      Apr 28, 05 16:01 ET Millennium Pharmaceuticals to Webcast 2005 Annual Meeting of Stockholders      07:05 ET Millennium Reports First Quarter VELCADE(R) (bortezomib) for Injection Sales Up 51%, R&D Expenses Down 11% Compared to First Quarter 2004   Apr 25, 05 08:02 ET VELCADE(R) (bortezomib) for Injection Phase II Clinical Trial Initiated in Lung Cancer      Apr 21, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on First Quarter Financial Results      Apr 13, 05 08:12 ET Studies of VELCADE(R) (bortezomib) for Injection Show Emerging Role as Cornerstone of Multiple Myeloma Care      08:06 ET Studies of VELCADE(R) (bortezomib) for Injection Show Emerging Role as Cornerstone of Multiple Myeloma Care      Apr 08, 05 08:18 ET Key Data on VELCADE(R) (Bortezomib) for Injection in Front-Line Studies and Beyond at the International Multiple Myeloma Workshop      Mar 28, 05 16:01 ET CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference to Webcast Millennium Presentation      11:38 ET Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for Injection in Second-Line Multiple Myeloma      Mar 25, 05 15:10 ET FDA Grants Full Approval for VELCADE(R) (Bortezomib) for Injection; Claims Include Survival Advantage and Use in Second-Line Multiple Myeloma      Mar 24, 05 16:52 ET Lehman Brothers Eighth Annual Global Healthcare Conference to Webcast Millennium Presentation      Mar 22, 05 16:01 ET Citigroup Smith Barney Healthcare Conference to Webcast Millennium Presentation      Mar 14, 05 08:04 ET Millennium Announces Senior Executive Appointments --Expands Key Leadership Roles and Promotes Senior Leaders From Within--   Mar 10, 05 16:01 ET SG Cowen & Co. 25th Annual Healthcare Conference to Webcast Millennium Presentation   08:02 ET Velcade(R) (bortezomib) for Injection Multiple Myeloma Retreatment Clinical Trial Initiated   Mar 08, 05 16:01 ET Data Support the Positive Clinical Benefits of GP IIb-IIIa Inhibitors and INTEGRILIN(R) (eptifibatide) Injection      Mar 07, 05 16:01 ET Millennium Achieves Milestone Payments of Approximately $40 Million      Mar 01, 05 08:03 ET INTEGRILIN(R) (Eptifibatide) Injection When Added to Clopidogrel Provided Superior Platelet Inhibition and Reduced Heart Muscle Death, Based on the Release of Cardiac Necrosis Biomarkers      Feb 22, 05 16:01 ET Millennium to Participate in the SunTrust Robinson Humphrey 'Off the Cuff' Therapeutics Conference      Feb 20, 05 08:01 ET Millennium Announces Promising Findings from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial      Feb 03, 05 08:02 ET Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation      Feb 01, 05 08:02 ET VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Non-Hodgkin's Lymphoma      Jan 27, 05 07:03 ET Millennium Reports Year End and Fourth Quarter 2004 Financial Results      Jan 25, 05 08:04 ET Millennium and UCB Pharma Enter Into Agreement to Collaborate on Two Biotherapeutic Inflammation Programs      Jan 20, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Fourth Quarter and Full-Year 2004 Financial Results      Jan 10, 05 08:09 ET Millennium to Highlight 2004 Accomplishments and 2005 Outlook at JPMorgan 23rd Annual Healthcare Conference      08:04 ET VELCADE(R) (bortezomib) for Injection Phase III Clinical Trial Initiated In Patients With Newly Diagnosed Multiple Myeloma      Jan 06, 05 16:01 ET Millennium to Webcast Business Update Conference Call on January 10, 2005 in Advance of JP Morgan Conference Presentation      Jan 05, 05 16:01 ET JP Morgan 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 20, 04 08:32 ET Millennium Announces Changes in Commercial Management and Board of Directors      Dec 15, 04 08:01 ET Millennium Receives Top Industry Awards      Dec 14, 04 08:01 ET Groundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis Disease Severity      Dec 06, 04 20:30 ET VELCADE(R) (Bortezomib) for Injection Studies Results Indicate Potential Utility Across the Multiple Myeloma Treatment Paradigm      19:42 ET VELCADE(R) (bortezomib) for Injection Continues to Provide Responses In Several Subtypes of Non-Hodgkin's Lymphoma      Dec 01, 04 08:24 ET FDA Accepts sNDA Filing with Priority Review for VELCADE(R) (bortezomib) for Injection to Treat Second-Line Multiple Myeloma      08:02 ET New Data on VELCADE(R) (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting      Nov 29, 04 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event Monday, December 6, 2004 7:00 P.M. PST (10:00 P.M. EST)      Nov 23, 04 16:01 ET Lazard Annual Life Sciences Conference to Webcast Millennium Presentation      Nov 09, 04 16:16 ET Millennium Announces Webcast of R&D Day 2004 Presentations      Nov 08, 04 08:04 ET New Clinical Trial Data Showed the Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone      Nov 06, 04 18:15 ET New Data Reveal Clinical Differences Between INTEGRILIN (R) (Eptifibatide) Injection and Bivalirudin      Nov 03, 04 16:07 ET CIBC World Markets Fifteenth Annual Healthcare Conference to Webcast Millennium Presentation      Nov 02, 04 16:15 ET FDA Grants VELCADE(R) (bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma      Oct 28, 04 08:51 ET Millennium Reports Third Quarter 2004 Financial Results;      07:02 ET Millennium Reports Third Quarter 2004 Financial Results;      Oct 20, 04 16:13 ET Millennium Pharmaceuticals to Webcast Conference Call on Third Quarter 2004 Financial Results      Oct 18, 04 08:02 ET Millennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis      Oct 14, 04 16:01 ET Millennium Files Post-Effective Amendment to S-3 Registration Statement      Oct 05, 04 16:01 ET Millennium Appoints New General Counsel      Sep 29, 04 08:25 ET Millennium Files Supplemental New Drug Application for VELCADE(R) (Bortezomib) for Injection for the Treatment of Patients with Second-Line Multiple Myeloma      Sep 20, 04 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Presentation      Sep 14, 04 16:01 ET Banc of America Securities 34th Annual Investment Conference to Webcast Millennium Presentation      Sep 07, 04 16:01 ET Newsmakers in the Biotech Industry Conference to Webcast Millennium Presentation      Aug 18, 04 07:59 ET VELCADE(R) (bortezomib) for Injection Named Oncology Compound of the Year at the 2004 Pharmaceutical Achievement Awards      Jul 29, 04 12:10 ET Millennium Appoints Marsha Fanucci Chief Financial Officer      Jul 22, 04 07:02 ET Millennium Reports Second Quarter 2004 Financial Results      Jul 16, 04 08:00 ET Millennium Pharmaceuticals to Webcast Conference Call on Second Quarter 2004 Financial Results      Jun 23, 04 08:01 ET Millennium and GlaxoSmithKline Announce INTEGRILIN(R) (Eptifibatide) Injection Licensing Agreement for Europe      Jun 06, 04 14:00 ET Millennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer      09:01 ET VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients with Previously Untreated Multiple Myeloma      Jun 05, 04 11:01 ET VELCADE(R) (Bortezomib) for Injection Data Show a Significant Improvement In Survival in Patients With Relapsed Multiple Myeloma      Jun 02, 04 16:01 ET Goldman Sachs Twenty Fifth Annual Global Healthcare Conference to Webcast Millennium Presentation      07:59 ET Millennium Acquires Rights to Novel Proteasome Inhibitors and Related Synthesis Techonology      Jun 01, 04 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society Of Clinical Oncology Investor Event      07:19 ET Millennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN(R) (eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting      May 17, 04 16:01 ET Millennium Announces VELCADE(R) (bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients with Relapsed Multiple Myeloma      May 13, 04 16:01 ET Banc of America Securities Health Care Conference 2004 to Webcast Millennium Presentation      07:59 ET Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma      Apr 30, 04 16:01 ET Millennium Pharmaceuticals to Webcast 2004 Annual Meeting of Stockholders      Apr 28, 04 16:04 ET Millennium Reports First Quarter 2004 Financial Results      Apr 27, 04 12:15 ET European Commission Grants Marketing Authorization to Millennium for VELCADE(R) (Bortezomib)      Apr 22, 04 16:01 ET Millennium Pharmaceuticals To Webcast Conference Call on First Quarter 2004 Financial Results   Apr 01, 04 08:03 ET Millennium and NCI Collaborate to Investigate Role of ACE2 in Connection with SARS   Mar 17, 04 07:59 ET Millennium Announces FDA Selection of MLN2704 for Continuous Marketing Application Pilot 2 Program      Mar 02, 04 16:01 ET SG Cowen 24th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Feb 25, 04 16:01 ET Lehman Brothers Seventh Annual Global Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Jan 27, 04 16:04 ET Millennium Reports Year End and Fourth Quarter 2003 Financial Results      Jan 22, 04 11:50 ET VELCADE(TM) (Bortezomib) Recommended for European Marketing Approval      Jan 20, 04 16:01 ET Millennium Pharmaceuticals, Inc. to Webcast Conference Call on Year End And Fourth Quarter 2003 Financial Results on January 28, 2004      Jan 12, 04 08:33 ET Millennium to Highlight 2004 Financial Outlook and Goals at JPMorgan Healthcare Conference      Jan 06, 04 12:07 ET Millennium Responds to Media Reports Related to Closure Of Phase II VELCADE Colorectal Trial      Jan 05, 04 13:47 ET JP Morgan 22nd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Dec 22, 03 08:07 ET Millennium Initiates Phase I Clinical Trial of MLN3897   Dec 15, 03 05:25 ET Independent Committee Recommends Early End to Confirmatory Phase III VELCADE Trial Based on Achieving Statistically Significant Improvement in Primary Endpoint      Dec 11, 03 14:00 ET Early Research Advances Field of Proteasome Biology      Dec 09, 03 16:01 ET Preliminary Study Results of VELCADE(TM) (bortezomib) for Injection Combined With Thalidomide Demonstrated Anti-Tumor Activity in Patients With Advanced Multiple Myeloma      Dec 08, 03 18:30 ET New Phase II Findings Support Potential Role of VELCADE(TM) (bortezomib) for Injection in Patients With Non-Hodgkin's Lymphoma      08:03 ET Preliminary Phase II Results With VELCADE(TM) (Bortezomib) For Injection Demonstrated Activity In Patients With Previously Untreated Multiple Myeloma      Dec 04, 03 07:59 ET FDA Grants Millennium Fast Track Status for MLN2704      Dec 03, 03 08:19 ET New Data on VELCADE(TM) (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting      Dec 01, 03 16:01 ET Millennium Announces Webcast of American Society of Hematology Investor Event      Nov 04, 03 17:09 ET CIBC World Markets Fourteenth Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Oct 27, 03 08:24 ET Millennium and Bayer's Successful Research Collaboration Concludes      Oct 15, 03 16:11 ET Millennium Reports Third Quarter 2003 Financial Results      Oct 14, 03 07:59 ET Millennium Initiates Phase II Clinical Trial With MLN1202 in Patients With Rheumatoid Arthritis      Oct 09, 03 16:02 ET Millennium Pharmaceuticals Announces Webcast Of Analyst And Investor Day Presentations      08:03 ET Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients with Metastatic Androgen-Independent Prostate Cancer      Sep 26, 03 07:59 ET Millennium Announces Assignment of Medicare Code for VELCADE(TM) (bortezomib) for Injection      Sep 22, 03 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Sep 19, 03 15:38 ET Correction to Press Release: New Data Show Early Use of Anti-Platelet Therapy Reduced Combined Death or Subsequent Heart Attacks in High-Risk Heart Attack Patients      Sep 17, 03 15:36 ET New Data Show Early Use Of Anti-Platelet Therapy Reduced Combined Death Or Subsequent Heart Attacks In High-Risk Heart Attack Patients      Aug 28, 03 16:01 ET Newsmakers in the Biotech Industry Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Aug 22, 03 08:11 ET Julian Adams, Ph.D. to Join Infinity as Chief Scientific Officer   08:09 ET Millennium Announces Changes in R&D Management      Jul 22, 03 07:31 ET Millennium Reports Second Quarter 2003 Financial Results      Jul 16, 03 16:04 ET Millennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003      Jul 10, 03 07:59 ET Millennium Announces Changes in Senior Management      Jul 03, 03 02:00 ET Millennium and Xenova Initiate Phase I Clinical Trial Of MLN944      Jul 02, 03 08:00 ET Millennium Initiates Phase II Clinical Trial with VELCADE(TM) (Bortezomib) for Injection in Patients with Relapsed or Refractory Mantle Cell Lymphoma      Jun 30, 03 16:02 ET Millennium Enters Into Commercialization and Development Agreement With Ortho Biotech Products, L.P., for VELCADE(TM) (Bortezomib) For Injection      Jun 25, 03 17:00 ET Velcade(TM) (Bortezomib) for Injection Phase II (Summit) Multiple Myeloma Study Results Published in the New England Journal of Medicine   Jun 05, 03 09:30 ET Millennium Announces Restructuring      Jun 04, 03 16:01 ET Goldman Sachs Healthcare Conference to Webcast Millennium Pharmaceuticals P